Back to search results

At-Home BCG Treatment for Bladder Cancer

This study is exploring a new way to deliver BCG (Bacillus Calmette-Guérin) treatment for bladder cancer at home. BCG is a type of immunotherapy often used for non-muscle invasive bladder cancer. The study aims to see if giving BCG at home is practical and effective. It will also use a chatbot, called BB-Bot, to help measure your symptoms and how you're feeling. You might be able to join if you are 18 or older and have completed intravesical treatment (treatment given directly into the bladder) for non-muscle invasive bladder cancer within the last year. The main goal is to see how well people stick to their BCG treatment plan after three months. The current recruitment status is unclear, and the study plans to enroll 50 participants.

Study design
This is a single-arm pilot study, meaning all participants will receive the same intervention. It aims to enroll 50 participants.
What's involved
Participants in the second group will use a conversational agent (chatbot) to track their symptoms and quality of life.
Compensation
Not stated in the trial record.
Follow-up
Adherence to BCG therapy will be measured at 3 months after the study starts.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07048496

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

Recruiting
NAAges 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~50 participants
Updated 2026-05-13 on ClinicalTrials.gov
What's tested:BCG delivery at home

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of adherence to BCG therapy at 3 months after study initiation
Measured over 3 months after study initiation

Conditions

Bladder Cancer

Explore related trials

Bladder Carcinoma

NCT07048496

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Abramson Cancer Center

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Daniel Lee, PI, MD
[email protected]
215-615-3780
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older;
Age 18 years or older;
experience with the delivery of BCG delivery for more than 2 years
Age 18 years or older;
diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy

Exclusion

inability to provide informed consent
inability to undergo catheterization (i.e. - history of urethral stricture)
inability to receive BCG therapy (i.e. - previous reaction with BCG)
no access to mobile phone
inability to respond to written conversations in English

What this trial measures

  • Rate of adherence to BCG therapy at 3 months after study initiation3 months after study initiation

    The primary outcome will be the rate of adherence to AUA guidelines for BCG therapy as measured by successful treatments of BCG compared to expected treatments. For each participant, adherence will be calculated both as the percentage of adherent doses, evaluable for study participants